Search Result
Results for "
GPR40
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-147351
-
-
-
- HY-103083
-
-
-
- HY-12647
-
-
-
- HY-111763
-
-
-
- HY-147678
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-172944
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 Activator 3 (compound SC) is a potent GPR40 activator. GPR40 Activator 3 mitigates pulmonary fibrosis by inhibiting M2 macrophage polarization via the GPR40/PKD1/CD36 axis .
|
-
-
- HY-U00395
-
-
-
- HY-111359
-
-
-
- HY-162136
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 agonist 7 (Compound 1) is an orally active G protein-coupled receptor 40 (GPR40) agonist. GPR40 agonist 7 can significantly increase insulin and GLP-1 secretion, and has a hypoglycemic effect in vivo with an ED50 of 0.58 mg/kg
|
-
-
- HY-13971
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 Activator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-112603A
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AP5 sodium is a potent, orall active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 sodium demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 sodium has the potential for type II diabetes research .
|
-
-
- HY-112603
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AP5 is a potent, orlly active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 has the potential for type II diabetes research .
|
-
-
- HY-12585
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AM-4668 is a GPR40 agonist for type 2 diabetes. EC50s of 3.6 nM and 36 nM for GPR40 in A9 cells (GPR40 IP3 assay) and CHO cells (GPR40 aequorin assay), respectively .
|
-
-
- HY-19835
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
LY2922470 is a selective and orally active agonist for the G protein-coupled receptor 40 (GPR40). LY2922470 activates GPR40-mediated β-arrestin recruitment with EC50s of 7 nM (human GPR40), 1 nM (mouse GPR40) and 3 nM (rat GPR40). LY2922470 can be used for research of type 2 diabetes mellitus (T2DM) .
|
-
-
- HY-147420
-
|
IDG-16177
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
Xelaglifam is a potent GPR40 agonist. Antihyperglycaemic activity . Xelaglifam is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-16619
-
-
-
- HY-129707
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 hemicalcium inhibits specific [ 3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents .
|
-
-
- HY-117978
-
|
|
Free Fatty Acid Receptor
|
Endocrinology
|
|
LY2922083 and related compounds LY2881835 and LY2922470 are spiperidine and tetrahydroquinolinic acid derivatives that are potent GPR40 agonists. LY2922083 activates GPR40 in response to elevated blood glucose and has the potential to be a glucose-lowering agent .
|
-
-
- HY-15589
-
|
|
Free Fatty Acid Receptor
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
|
-
-
- HY-13467
-
-
-
- HY-50691
-
-
-
- HY-10480
-
-
-
- HY-101906
-
|
|
Free Fatty Acid Receptor
Apoptosis
|
Metabolic Disease
|
|
DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca 2+ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC50: 6.28, 5.96, 7.07, 4.58 μM, respectively) . DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis .
|
-
-
- HY-123297
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .
|
-
-
- HY-15589R
-
|
|
Free Fatty Acid Receptor
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
|
-
-
- HY-13967B
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [ 3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents . AMG 837 (calcium hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-141653
-
-
-
- HY-132265
-
-
-
- HY-111116
-
-
-
- HY-10480A
-
|
(R)-TAK-875
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
(R)-Fasiglifam is the isomer of Fasiglifam (HY-10480), and can be used as an experimental control. Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.
|
-
-
- HY-50691R
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GW-1100 (Standard) is the analytical standard of GW-1100. This product is intended for research and analytical applications. GW-1100 is a selective GPR40 antagonist with a pIC50 of 6.9.
|
-
-
- HY-130120
-
|
|
Free Fatty Acid Receptor
PPAR
|
Metabolic Disease
|
|
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC50 of 18.9 nM) with moderate PPARδ activity (EC50 of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .
|
-
-
- HY-P1124
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AS2034178 free base, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. AS2034178 free base has potential for type 2 diabetes mellitus research .
|
-
-
- HY-100775
-
|
Setogepram sodium; PBI-4050 sodium
|
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis . Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
-
- HY-100775A
-
|
Setogepram; PBI-4050
|
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
-
- HY-117787
-
-
-
- HY-P1123
-
|
|
ATP Citrate Lyase
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120 .
|
-
-
- HY-124571
-
|
|
GPR84
|
Inflammation/Immunology
|
|
ZQ-16 is a potent and selective GPR84 agonist with an EC50 value of 0.213 μM. ZQ-16 has no activity on the other free fatty acid receptors (FFARs), including GPR40, GPR41, GPR119 and GPR120 .
|
-
-
- HY-B1021
-
|
|
Free Fatty Acid Receptor
|
Cardiovascular Disease
Metabolic Disease
|
|
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .
|
-
-
- HY-W010655
-
|
TAK-875 hemihydrate
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC50 of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .
|
-
-
- HY-160602
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
|
-
-
- HY-108020
-
|
|
Free Fatty Acid Receptor
|
Endocrinology
|
|
LY2881835 is a potent and selective agonist of G protein-coupled receptor 40 (GPR40). LY2881835 has efficacious and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion. LY2881835 has the potential for the research of type 2 diabetes mellitus . LY2881835 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-12413A
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
BMS-986118 is a potent, orally active, and selective GPR40 agonist with an EC50 of 0.07 µM. BMS-986118 has dual insulinotropic and GLP-1 secretory effects, resulting in robust plasma glucose lowering effects in acute animal models .
|
-
-
- HY-148247
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
BI-2081 is a GPR40 (FFAR1) partial agonist (EC50: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2 .
|
-
-
- HY-148418
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC50 of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-100775R
-
|
Setogepram sodium (Standard); PBI-4050 sodium (Standard)
|
Reference Standards
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (sodium) (Standard) is the analytical standard of Fezagepras (sodium). This product is intended for research and analytical applications. Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis . Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
-
- HY-100775AR
-
|
Setogepram (Standard); PBI-4050 (Standard)
|
Reference Standards
Free Fatty Acid Receptor
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Fezagepras (Standard) is the analytical standard of Fezagepras. This product is intended for research and analytical applications. Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
|
-
-
- HY-B1021R
-
|
|
Reference Standards
Free Fatty Acid Receptor
|
Cardiovascular Disease
Metabolic Disease
|
|
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .
|
-
-
- HY-14363
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-176733
-
|
|
HDAC
Free Fatty Acid Receptor
Microtubule/Tubulin
ERK
|
Neurological Disease
|
|
HDAC6-IN-61 (Compound 4e) is a HDAC6 inhibitor (IC50: 73 nM) with selectivity over other HDAC isoforms. HDAC6-IN-61 is also a GPR40 activator. HDAC6-IN-61 increases acetylated tubulin and ERK phosphorylation levels. HDAC6-IN-61 can be used for research of neuroinflammation such as Alzheimer's disease .
|
-
- HY-15697
-
TUG-770
3 Publications Verification
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC50 of 6 nM for human FFA1. TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research . TUG-770 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-168168
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues .
|
-
- HY-RS23415
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ffar1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ffar1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ffar1 Rat Pre-designed siRNA Set A
Ffar1 Rat Pre-designed siRNA Set A
- HY-RS16972
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ffar1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ffar1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ffar1 Mouse Pre-designed siRNA Set A
Ffar1 Mouse Pre-designed siRNA Set A
- HY-RS04874
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
FFAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FFAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
FFAR1 Human Pre-designed siRNA Set A
FFAR1 Human Pre-designed siRNA Set A
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-RS23415
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Ffar1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ffar1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS16972
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Ffar1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ffar1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS04874
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
FFAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FFAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
